High-Dose Omega-3 and Atrial Fibrillation: An Unexpected Side Effect?

Omega-3 fatty acids, covered in more depth in our knowledge-base entry, have for decades been associated almost exclusively with benefits: a healthier lipid profile, anti-inflammatory effects, support for cognitive function. At typical over-the-counter doses (usually 1-2g/day), the safety profile is indeed very good. Far less is said, however, about what large, randomized clinical trials have shown when evaluating doses many times higher — 4g/day — used therapeutically in patients at elevated cardiovascular risk.

Two independent clinical trials from recent years, evaluating two different omega-3 formulations at this high dose, reached very different conclusions about overall cardiovascular benefit — but consistently showed the same concerning side effect: a significantly elevated risk of new-onset atrial fibrillation, the irregular, chaotic rhythm of the heart's upper chambers. That's a convergence hard to ignore, even though it involved two different omega-3 formulations in two different patient populations.

The starting point is REDUCE-IT, one of the most influential cardiology trials of the past decade, evaluating purified EPA (icosapent ethyl) at 4g/day in statin-treated patients with elevated triglycerides.

It's worth pausing on these numbers: the difference between 3.1% and 2.1% represents a relative increase in atrial fibrillation hospitalization risk of nearly 48% in the group taking the high dose of purified EPA. That's not a borderline or random statistical blip — a P value of 0.004 indicates an effect unlikely to be explained by chance alone. And yet, on balance, REDUCE-IT remains a trial that showed a real benefit — a 4.8 percentage point absolute reduction in the primary composite endpoint is a result rarely seen in preventive cardiology.

A natural question after REDUCE-IT was whether a similar pattern (benefit plus atrial fibrillation risk together) would recur with a different omega-3 formulation. The answer comes from the STRENGTH trial, which evaluated a mixture of EPA and DHA in carboxylic acid form, also at 4g/day, this time compared against corn oil as the placebo.

STRENGTH wasn't originally designed to study atrial fibrillation risk in detail — but the data collected allowed for a dedicated secondary analysis, published in 2026, focused specifically on this question in patients with no prior history of the arrhythmia.

Working through these numbers: 2.1% versus 1.2% represents a relative increase in new-onset atrial fibrillation risk of nearly 75% in the group taking the high-dose omega-3, compared to placebo — even more pronounced in relative terms than the signal observed in REDUCE-IT. The fact that two independent, large clinical trials, evaluating two different omega-3 formulations in two different cardiac patient populations, showed the same direction of effect substantially strengthens confidence in the conclusion that high-dose omega-3 genuinely raises the risk of this specific arrhythmia — regardless of whether the supplement itself delivers an overall cardiovascular benefit.

The exact mechanism linking high-dose omega-3 to elevated atrial fibrillation risk isn't yet fully established, but the leading hypothesis concerns omega-3's effect on ion channel function in cardiomyocyte cell membranes. At high concentrations, omega-3 fatty acids can incorporate into heart muscle cell membranes and alter the electrical conduction of the atria, potentially shortening refractory periods or changing tissue excitability in a way that favors the initiation and persistence of abnormal rhythms.

Notably, this proposed mechanism concerns omega-3 concentrations far exceeding those achieved with typical, low-dose over-the-counter supplementation. That's consistent with what the clinical trials themselves show: the atrial fibrillation risk signal consistently appeared at the 4g/day dose, not at doses around 1g/day typical of popular fish oil supplements.

Atrial fibrillation can be asymptomatic and discovered incidentally during a routine exam, but in some patients it produces clear, recognizable symptoms. People starting high-dose omega-3 therapy should know these symptoms and know when to see a doctor, rather than waiting for the next scheduled check-up.

This is a rare and instructive case where two large, randomized clinical trials, evaluating two different formulations of the same supplement in two different but related patient populations, reach starkly different conclusions about the main clinical benefit, while agreeing on a specific side effect. This convergence on atrial fibrillation risk, despite the divergence on cardiovascular benefit, makes the risk signal credible and worth raising with a doctor — without drawing conclusions from it beyond what the data actually shows.